Due to the now-routine use of next generation sequencing in clinical diagnostics, it is likely that information regarding genetic variation in the TTN gene and the group of TTN-related myopathies will continue to expand massively in the coming years, emphasizing the need for a structured approach to pathogenicity assessment and to establish reliable genotype–phenotype correlations. This evidence concerns the gene TTN and myopathy.